An Open-Label Study of XOMA 358, with Optional Dose Escalation, in Patients with Congenital Hyperinsulinism

Trial Profile

An Open-Label Study of XOMA 358, with Optional Dose Escalation, in Patients with Congenital Hyperinsulinism

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs XOMA 358 (Primary)
  • Indications Hyperinsulinaemia; Hypoglycaemia
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors XOMA
  • Most Recent Events

    • 04 Apr 2017 Results assessing activity of Xoma-358, following short-term administration to congenital hyperinsulinism patients (X358602 and X358605 Congenital Hyperinsulinism studies), presented at The 99th Annual Meeting of the Endocrine Society.
    • 19 Sep 2016 New trial record
    • 15 Sep 2016 According to XOMA media release, updates from this and other three studies of XOMA-358 were presented in a webcast on 15 Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top